Filgrastim, a recombinant granulocyte colony-stimulating factor (G-CSF), and sargramostim, a recombinant granulocytemacrophage colony-stimulating factor (GM-CSF), have been available in the United ...
During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic ...
With the CSF-1R inhibitor space heating up, Merck KGaA has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 ...
FORT LAUDERDALE, FL / ACCESS Newswire / April 3, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a ...
The following is a summary of “Favorable correlation between neutrophil percentages obtained using automated hematology ...
Hosted on MSN11mon
Health Canada approves Nora Pharma for commercialisation of NIOPEGNiopeg is a long-acting form of recombinant human granulocyte colony-stimulating factor or filgrastim. It is specifically indicated to decrease the incidence of infection, as manifested by febrile ...
Merck KGaA is exercising its option for a global license to commercialize Abbisko Therapeutics Co. Ltd.’s pimicotinib for $85 million. As previously reported by BioWorld, Abbisko out-licensed China ...
The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback